Wealthspire Advisors (New York)’s Mereo BioPharma MREO Stock Holding History

Wealthspire Advisors (New York)’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$243K	Sell	765,000 -31,036	-4%	-$9.31K	﹤0.01%	1087
2026 Q1	$263K	Buy	+796,036	New	+$342K	﹤0.01%	767
2025 Q4	–	Sell	-1,026	Closed	-$2.11K	–	2175
2025 Q3	$2.11K	Buy	+1,026	New	+$1.89K	﹤0.01%	2597
2022 Q1	–	Sell	-19,276	Closed	-$31K	–	506
2021 Q4	$31K	Buy	+19,276	New	+$38.5K	﹤0.01%	533
2021 Q3	–	Sell	-14,276	Closed	-$45K	–	591
2021 Q2	$45K	Hold	14,276	–	–	﹤0.01%	365
2021 Q1	$48K	Hold	14,276	–	–	﹤0.01%	698
2020 Q4	$51K	Buy	+14,276	New	+$35.8K	﹤0.01%	572
2020 Q2	–	Sell	-14,276	Closed	-$15K	–	441
2020 Q1	$15K	Buy	+14,276	New	+$24.7K	﹤0.01%	556

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Wealthspire Advisors (New York)'s MREO Position: Q2 2026 in Review

Wealthspire Advisors (New York) reduced its Mereo BioPharma (MREO) stake by 3.9% in Q2 2026, selling an estimated $9.31K and leaving 765,000 shares worth $243K. The position accounts for ﹤0.01% of the portfolio, ranked #1087.

Wealthspire Advisors (New York) first reported a position in MREO in Q1 2020 and has held it in 8 quarters since. The position peaked at $263K in Q1 2026. 61 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

Wealthspire Advisors (New York) held 765,000 shares of Mereo BioPharma worth $243K as of Q2 2026.
Wealthspire Advisors (New York) sold 31,036 Mereo BioPharma shares in Q2 2026, an estimated $9.31K.
Mereo BioPharma made up ﹤0.01% of Wealthspire Advisors (New York)'s portfolio in Q2 2026, its #1087 holding.
Wealthspire Advisors (New York) first reported a position in Mereo BioPharma in Q1 2020 and has held it in 8 quarters since.
Wealthspire Advisors (New York)'s Mereo BioPharma position peaked at $263K in Q1 2026.
61 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q2 2026, filed 11 Aug 2026.